Celyad Oncology SA (CLYYF)

Market Cap	13.95M -31.5%
Revenue (ttm)	24.66K -88.7%
Net Income	974.52K
EPS	0.02
Shares Out	n/a
PE Ratio	14.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,868
Open	0.2800
Previous Close	n/a
Day's Range	0.2800 - 0.2800
52-Week Range	0.1500 - 0.4100
Beta	1.21
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLYYF

Financial Performance

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error